We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+7.33%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$123M
AUM Growth
+$7.42M
Cap. Flow
+$6.34M
Cap. Flow %
5.16%
Top 10 Hldgs %
65.43%
Holding
71
New
10
Increased
12
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
TECL icon
Direxion Daily Technology Bull 3x ETF
TECL
+$1.68M
2
PRTA icon
Prothena Corp
PRTA
+$1.5M
3
DCGO icon
DocGo
DCGO
+$960K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$794K
5
TMCI icon
Treace Medical Concepts
TMCI
+$622K

Top Sells

Rank Stock Value
1
ATEC icon
Alphatec Holdings
ATEC
+$1.12M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1M
3
ELUT icon
Elutia
ELUT
+$371K
4
PGNY icon
Progyny
PGNY
+$369K
5
CHRS icon
Coherus Oncology
CHRS
+$325K

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Energy 3.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
51
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$275K 0.22%
7,365
– –
FOLD
52
DELISTED
Amicus Therapeutics
FOLD
$264K 0.21%
28,000
– –
CGEM icon
53
Cullinan Oncology
CGEM
$1.08B
$244K 0.2%
20,000
– –
KROS icon
54
Keros Therapeutics
KROS
$209M
$237K 0.19%
15,000
+8,000
+114% +$416K
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$235K 0.19%
2,700
– –
MLTX icon
56
MoonLake Immunotherapeutics
MLTX
$1.59B
$217K 0.18%
+4,000
New +$204K
ZBIO
57
Zenas BioPharma
ZBIO
$1.97B
$135K 0.11%
+16,500
New +$257K
TECL icon
58
Direxion Daily Technology Bull 3x ETF
TECL
$5.22B
$128K 0.1%
+18,000
New +$1.68M
GOSS icon
59
Gossamer Bio
GOSS
$71.2M
$125K 0.1%
138,176
– –
IFRX icon
60
InflaRx
IFRX
$268M
$124K 0.1%
50,000
– –
LQDA icon
61
Liquidia Corp
LQDA
$6.94B
$118K 0.1%
10,000
– –
CHRS icon
62
Coherus Oncology
CHRS
$219M
$113K 0.09%
82,000
-290,000
-78% -$325K
NPCE icon
63
Neuropace
NPCE
$536M
$112K 0.09%
+10,000
New +$86.9K
ALMS
64
Alumis Inc
ALMS
$3.58B
$78.6K 0.06%
10,000
– –
VTYX
65
DELISTED
Ventyx Biosciences
VTYX
$63.1K 0.05%
28,800
– –
ZNTL icon
66
Zentalis Pharmaceuticals
ZNTL
$359M
$51.5K 0.04%
17,000
+1,000
+6% +$3.28K
TSVT
67
DELISTED
2seventy bio
TSVT
$46.5K 0.04%
15,833
– –
CERO
68
DELISTED
CERo Therapeutics
CERO
$778 ﹤0.01%
6
– –
BLUE
69
DELISTED
bluebird bio
BLUE
– –
-10,560
Closed -$110K
CABA icon
70
Cabaletta Bio
CABA
$452M
– –
-10,000
Closed -$47.2K
PGNY icon
71
Progyny
PGNY
$2.5B
– –
-22,000
Closed -$369K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Birchview Capital held 71 positions worth $123M, up 6.4% from $115M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Birchview Capital deployed $6.34M of net new capital in Q4 2024, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was Alphatec Holdings, an estimated $1.12M trimmed.

  • Birchview Capital's largest Q4 2024 buy was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.
  • Birchview Capital added most to Prothena Corp in Q4 2024, an estimated $1.5M increase.
  • Birchview Capital's biggest Q4 2024 reduction was Alphatec Holdings, cutting an estimated $1.12M.
  • Birchview Capital fully exited Progyny in Q4 2024, selling an estimated $369K.
  • Birchview Capital's ten largest holdings make up 65% of its $123M portfolio in Q4 2024.
  • Birchview Capital opened 10 new positions and closed 3 in Q4 2024.
  • Birchview Capital's portfolio value rose 6.4% quarter-over-quarter to $123M.

Based on Birchview Capital's 13F filing for Q4 2024, filed 14 Feb 2025.